Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
ACP-204 by Acadia Pharmaceuticals for Psychosis: Likelihood of Approval
ACP-204 is under clinical development by Acadia Pharmaceuticals and currently in Phase III for Psychosis. According to GlobalData, Phase III...
Data Insights
ACP-204 by Acadia Pharmaceuticals for Alzheimer's Disease: Likelihood of Approval
ACP-204 is under clinical development by Acadia Pharmaceuticals and currently in Phase III for Alzheimer's Disease. According to GlobalData, Phase...